We thank the patients enrolled in this study as well as our fellow clinicians and scientists for providing outstanding clinical care and laboratory work despite considerable personal risk. Members of the Collaboration for Clinical and Laboratory Characterization of COVID-19 in Uganda are as follows: National Influenza Center, Department of Arbovirology, Emerging and Re-emerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda (Barnabas Bakamutumaho, Nicholas Owor, John Kayiwa, Joyce Namulondo, Timothy Byaruhanga, Julius J. Lutwama, Joweria Nakaseegu, Jocelyn Kiconco, Annet Nankya, Irene Ataliba, Samuel Wavamuno); Viral Hemorrhagic Fever Program, Uganda Virus Research Institute, Entebbe, Uganda (Stephen Balinandi, Luke Nyakaruhuka, Jimmy Baluku, Alex Tumusiime, Jackson Kyondo, Sophia Mulei, Kilama Kamugisha, Gloria Akurut, Diana Nahamya); Immunisable Diseases Unit/Expanded Programme on Immunisation Laboratory, Uganda Virus Research Institute, Entebbe, Uganda (Peter Eliku, Phiona Tushabe, Joshua Buule, Joseph Gaizi, Prossy Namuwulya, Arnold Mugaga, Mary Nyacho, Henry Bukenya, Josephine Bwogi); European and Developing Countries Clinical Trials Partnership-Eastern Africa Consortium for Clinical Research, Uganda Virus Research Institute, Entebbe, Uganda (Bernard Kikaire); Entebbe Regional Referral Hospital, Entebbe, Uganda (Moses Muwanga, Christopher Nsereko, Emmanuel Rwamutwe, Roselyn Mutonyi, Josephine Achan, Lucy Wanyenze, Alice Ndazarwe, Ruth Nakanjako, Richard Natuhwera, Annet Nsangi); Uganda Peoples’ Defence Force, Kampala, Uganda (Henry Kyobe Bosa); Public Health Emergency Operations Centre, Ministry of Health, Kampala, Uganda (Felix Ocom); Makerere University School of Public Health, Kampala, Uganda (James Arinaitwe); Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, USA (Matthew J. Cummings, Max R. O’Donnell). The American Society of Tropical Medicine and Hygiene has waived the Open Access fee for this article due to the ongoing COVID-19 pandemic.
Kirenga B et al., 2020. Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. BMJ Open Respir Res 7: e000646.
World Health Organization , 2021. A High-Level Overview of Emerging Issues in Each Phase of the Pandemic. Available at: https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update51_pandemic_overview_where_are_we_now.pdf?sfvrsn=709278aa_5. Accessed May 14, 2021.
Ministry of Health , 2021. National Guidelines for Management of COVID-19. Available at: https://www.health.go.ug/cause/national-guidelines-for-management-of-covid-19/. Accessed May 14, 2021.
Peckham H , de Gruijter NM , Raine C , Radziszewska A , Ciurtin C , Wedderburn LR , Rosser EC , Webb K , Deakin CT , 2020. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 11: 6317.
O’Driscoll M , Ribeiro Dos Santos G , Wang L , Cummings DAT , Azman AS , Paireau J , Fontanet A , Cauchemez S , Salje H , 2021. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590: 140–145.
Vermooten B et al., 2020. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis August 29: ciaa1198.
Morton B et al., 2021. Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. Nat Commun12: 3554.
Njenga MK , Dawa J , Nanyingi M , Gachohi J , Ngere I , Letko M , Otieno CF , Gunn BM , Osoro E , 2020. Why is there low morbidity and mortality of COVID-19 in Africa? Am J Trop Med Hyg 103: 564–569.
Africa Centres for Disease Control and Prevention , 2021. New SARS-CoV-2 Variants in Africa. Available at: https://africacdc.org/download/new-sars-cov-2-variants-in-africa/. Accessed May 14, 2021.
Allotey J et al. 202. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis BMJ 370: m3320.